Opinion on Biotech in Middle East and Africa

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Vertex Pharmaceuticals: strong evidence for VX-770 as a potential novel treatment method

Vertex Pharmaceuticals' novel cystic fibrosis treatment VX-770 has demonstrated strong efficacy in a Phase III trial, meeting the primary endpoint and key secondary endpoints. VX-770 targets the underlying cause of the disease, and, if approved, would offer a novel treatment approach.

Published By Datamonitor
25 Feb 2011
CommentWire
CommentWire

Top pharmaceutical and biotech companies face slowdown in sales growth over 2008-14

A Datamonitor report has identified that the leading pharmaceutical and biotech companies face a major slowdown in sales growth out to 2014, primarily a result of the imminent patent expiries facing many blockbusters and the subsequent threat from generics. Prescription sales are expected to rise at a compound annual growth rate of just 1.2% over 2008-14, compared to a historical rate of 10.5%.

Published By Datamonitor
01 Mar 2010
CommentWire
CommentWire

Roche: Q3 results highlight dependence on big three MAbs

Roche's Q3 2010 and year-to-date sales are down on the year prior, due primarily to a large decline in demand for the antiviral Tamiflu, although the company's impressive MAb trio of Avastin, Herceptin and MabThera continue to provide strong sales. However, Roche is looking to lower its dependency on these blockbusters, having inked a deal with InterMune for hepatitis C small molecule danoprevir.

Published By Datamonitor
14 Oct 2010
Expert View
Expert View

Roche/Genentech/Biogen Idec: Rituxan delays need for new therapy in follicular lymphoma

New data show that immediate treatment with Rituxan provides an impressive reduction in follicular lymphoma progression rates. These results could lead to a change in the management of newly diagnosed asymptomatic follicular lymphoma patients and increased uptake of Rituxan in the seven major markets.

Published By Datamonitor
13 Dec 2010
CommentWire
CommentWire

ICAD 2009: tau emerges as a viable target for immunotherapy in Alzheimer's

Despite being one of the two hallmarks for Alzheimer's disease for over a century, little drug development has focused on tau as a therapeutic target. At this year's International Conference for Alzheimer's Disease, two groups presented data suggesting the viability of tau as a target for vaccine development, offering an alternative target for companies keen to boost their neurology pipelines.

Published By Datamonitor
22 Jul 2009
Expert View
Expert View

ICAD 2009: beta-amyloid remains center stage at Alzheimer's disease conference

In recent years, the annual International Conference on Alzheimer's Disease has become the foremost event on the Alzheimer's disease calendar. As a primary hallmark of the disease, beta-amyloid production and deposition have become the focus for drug development. At this year's meeting progress was reported on several beta-amyloid targeted clinical stage pipeline drugs.

Published By Datamonitor
22 Jul 2009
CommentWire
CommentWire

Genentech/Roche: new trial failure marks setback for Avastin growth prospects

Multi-blockbuster Avastin has once again failed to show improved disease-free survival in a Phase III study for early-stage colon cancer. Although this will not impact Avastin's dominance in already approved indications, it is a major setback for development in the lucrative adjuvant therapy market and provides an opportunity for Erbitux.

Published By Datamonitor
22 Sep 2010
CommentWire
CommentWire

Genentech/Roche/Chugai: Herceptin shows activity in gastric cancer

Already a widely used therapy in HER-2-positive breast cancer patients, Herceptin now has the potential to establish itself in the equivalent gastric cancer subset following positive survival results in a pivotal trial. However, with other top-selling targeted therapy drugs also in late-stage development for the same indication, competition is on the horizon.

Published By Datamonitor
18 Mar 2009
Expert View
Expert View

AUA 2010: vaccine data and potential new treatments drive interest in prostate cancer

This year's meeting of the American Urological Association saw several major pharmaceutical players presenting new data and discussing potential new pathways for disease treatment. Among the areas of focus was prostate cancer, with Dendreon presenting new data for its groundbreaking vaccine Provenge and Amgen highlighting the potential of Prolia in the treatment of this disease.

Published By Datamonitor
04 Jun 2010
Expert View
Expert View

AUA 2010: encouraging new drugs in benign prostatic hyperplasia but challenges remain

Datamonitor attended this year's meeting of the American Urological Association, at which data were presented for two promising new candidates developed for the treatment of benign prostatic hyperplasia. Specifically, Watson Pharmaceuticals outlined the differentiators for its new treatment Rapaflo, while Nymox used the meeting to present new data for its pipeline drug NX-1207.

Published By Datamonitor
04 Jun 2010

« | 1 | 2 | » »|

No help is available.